Investor Overview

Investor Presentation
Financial News
Feb 14, 2019

Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, today reported financial results for the three and nine months...

Feb 7, 2019

Strong interim survival trend (15.2 vs 8.5 months) emerging in IL4R positive patients TORONTO and HOUSTON, TX, Feb. 7, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or "the Company")...

Feb 6, 2019

Magnified IL-2 affinity towards CD122 potently synergizes with checkpoint inhibitors TORONTO, Feb. 6, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA, OTCQB:...

Stock Quote
Stock Chart
Upcoming Events
Monday, February 11, 2019 - Tuesday, February 12, 2019

BIO CEO & Investor Conference New York, Marriott Marquis

Investor Contact
For more investor information, Please contact:
Elizabeth Williams, Chief Financial Officer
Email Alerts
* Required Fields